A recombinant COVID-19 fusion protein vaccine (V-01) developed and manufactured in China has been approved for phase-III clinical trials in the Philippines.
A recombinant Covid-19 fusion protein vaccine (V-01) developed and manufactured in China has been approved for phase-III clinical trials in the Philippines.
lianhua price philippines hicarquitectura.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from hicarquitectura.com Daily Mail and Mail on Sunday newspapers.
May 25, 2021
The national Social Weather Survey of April 28– May 2, 2021 found 63% of adult Filipinos choosing the United States of America (USA) as their preferred source of Covid-19 vaccines.
The survey also found Sinovac Biotech and Pfizer-BioNTech topping the list of preferred brands at 39% and 32%, respectively.
At the time of the survey, over 7 million Covid-19 vaccines have been delivered to the Philippines. Most of these vaccines are China’s Sinovac (about 5 million), followed by United Kingdom’s Oxford-AstraZeneca (about 2.5 million) and Russia’s Gamaleya Sputnik (about 30,000).
The first batch of Pfizer-BioNTech (around 193,000) COVID-19 vaccines arrived a week after the survey on May 10, 2021.
Published May 24, 2021, 12:22 PM
The Social Weather Stations (SWS) survey results released on Monday, May 24, found that at least three in 10 Filipinos prefer Sinovac and Pfizer as their brand of vaccines.
During the survey conducted from April 28 to May 2, 2021, SWS asked 1,200 adult respondents, “If you could choose the brand of vaccine approved by the Food and Drug Administration of the Philippines, which of the following would you choose?”
Respondents were provided with a list of 10 FDA-approved vaccines, presented in random order, and were allowed to choose more than one.
Topping the list were China’s Sinovac Biotech (39 percent) and US brand Pfizer-BioNTech (32 percent), followed by United Kingdom’s Oxford-AstraZeneca (22 percent), and US brand Johnson & Johnson (10 percent).